JP2015529664A5 - - Google Patents

Download PDF

Info

Publication number
JP2015529664A5
JP2015529664A5 JP2015528556A JP2015528556A JP2015529664A5 JP 2015529664 A5 JP2015529664 A5 JP 2015529664A5 JP 2015528556 A JP2015528556 A JP 2015528556A JP 2015528556 A JP2015528556 A JP 2015528556A JP 2015529664 A5 JP2015529664 A5 JP 2015529664A5
Authority
JP
Japan
Prior art keywords
cancer
combination
administered
organic solvent
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015528556A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015529664A (ja
JP6367801B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/055602 external-priority patent/WO2014031543A1/en
Publication of JP2015529664A publication Critical patent/JP2015529664A/ja
Publication of JP2015529664A5 publication Critical patent/JP2015529664A5/ja
Application granted granted Critical
Publication of JP6367801B2 publication Critical patent/JP6367801B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015528556A 2012-08-19 2013-08-19 化学療法耐性を克服するための、トリプテリジウム・ウィルフォルディ由来の抽出物の使用 Expired - Fee Related JP6367801B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261684792P 2012-08-19 2012-08-19
US61/684,792 2012-08-19
PCT/US2013/055602 WO2014031543A1 (en) 2012-08-19 2013-08-19 Tripterygium wilfordii extracts to overcome chemotherapy resistance

Publications (3)

Publication Number Publication Date
JP2015529664A JP2015529664A (ja) 2015-10-08
JP2015529664A5 true JP2015529664A5 (cg-RX-API-DMAC7.html) 2016-09-08
JP6367801B2 JP6367801B2 (ja) 2018-08-01

Family

ID=50150329

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015528556A Expired - Fee Related JP6367801B2 (ja) 2012-08-19 2013-08-19 化学療法耐性を克服するための、トリプテリジウム・ウィルフォルディ由来の抽出物の使用

Country Status (9)

Country Link
US (1) US10149876B2 (cg-RX-API-DMAC7.html)
EP (1) EP2888011A4 (cg-RX-API-DMAC7.html)
JP (1) JP6367801B2 (cg-RX-API-DMAC7.html)
CN (1) CN104797296B (cg-RX-API-DMAC7.html)
AU (2) AU2013306058A1 (cg-RX-API-DMAC7.html)
CA (1) CA2880575C (cg-RX-API-DMAC7.html)
HK (2) HK1212270A1 (cg-RX-API-DMAC7.html)
IN (1) IN2015DN01496A (cg-RX-API-DMAC7.html)
WO (1) WO2014031543A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014318623C1 (en) * 2013-09-13 2019-10-24 Western University Of Health Sciences Wilforlide A for overcoming chemotherapy resistance
CN111909119B (zh) * 2020-08-25 2023-06-16 上海诗丹德标准技术服务有限公司 雷公藤来源化合物及其应用和制备方法、药物组合物、杀虫剂

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991013627A1 (en) * 1990-03-14 1991-09-19 The Board Of Regents, The University Of Texas System Tripterygium wilfordii hook f extracts and components thereof for immunosuppression
US20060094775A1 (en) 2003-02-27 2006-05-04 Teruo Nishida Remedy for corneal ulcer
CN102443039B (zh) * 2010-10-14 2013-11-13 中国科学院上海药物研究所 N-取代氨基苯基-14β-氨甲基表雷公藤内酯醇衍生物及其制备方法和用途

Similar Documents

Publication Publication Date Title
JP2013522184A5 (cg-RX-API-DMAC7.html)
EA201890146A1 (ru) СПОСОБЫ ЛЕЧЕНИЯ СОЛИДНЫХ ОПУХОЛЕЙ С ИСПОЛЬЗОВАНИЕМ КОМБИНИРОВАННОЙ ТЕРАПИИ ИНГИБИТОРОМ mTOR В ВИДЕ НАНОЧАСТИЦ
WO2014145642A3 (en) Nrf2 small molecule inhibitors for cancer therapy
WO2007084670A3 (en) Specific therapy using integrin ligands for treating cancer
WO2016161342A3 (en) Nitrobenzyl derivatives of anti-cancer agents
EA201690905A1 (ru) Специфические антитела против cd38 для лечения злокачественных новообразований у человека
EA202092671A1 (ru) Оптимизированная комбинированная терапия и ее применение для лечения злокачественной опухоли и аутоиммунного заболевания
EA201491299A1 (ru) Карбаматные соединения, их получение и применение
RU2016112608A (ru) Лечение рака комбинацией плинабулина и таксана
WO2008087025A3 (en) Specific therapy and medicament using integrin ligands for treating cancer
EA201650134A1 (ru) Специфическая сочетанная терапия злокачественных опухолей цитостатиком и его модификатором
CL2014002097A1 (es) Compuestos derivados de tetrahidro-quinazolinona, inhibidores de tank y parp-1; proceso de preparacion; medicamentos; kit farmaceutico; uso en el tratamiento y/o la prevencion de cancer, esclerosis multiple, enfermedades cardiovasculares, lesion del sistema nervioso central.
ECSP16084317A (es) Formulaciones farmacéuticas, procesos para la preparación y métodos de uso
PH12015502616A1 (en) Pharmaceutical combination comprising metformin and dihydroquercetin and its use for the treatment of cancer
JP2014506233A5 (cg-RX-API-DMAC7.html)
EA201691570A1 (ru) Фармацевтическая композиция, включающая диамино-гетероциклическое карбоксамидное соединение в качестве активного ингредиента
MX2016015437A (es) Combinacion que comprende un glucocorticoide y edo-s101.
NZ716765A (en) Pharmaceutical combinations for the treatment of cancer
RU2017141536A (ru) Замещенные производные индол-5-ола и их терапевтические применения
JP2018522028A5 (cg-RX-API-DMAC7.html)
JP2017514854A5 (cg-RX-API-DMAC7.html)
RU2018107930A (ru) Агонисты tlr4, их композиции и применение для лечения рака
BR102012028120B8 (pt) Uso de um ou mais derivados de ingenol, composição farmacêutica e medicamento
WO2015038896A3 (en) Wilforlide a for overcoming chemotherapy resistance
RU2012108144A (ru) Противораковая терапия, направленная против раковых стволовых клеток и форм рака, устойчивых к лечению лекарственными препаратами